Lurbinectedin in the Treatment of Relapsed Small Cell Lung Cancer
Javier Baena, Andrea Modrego, Ali Zeaiter, Carmen Kahatt, Vicente Alfaro, E. Jimenez-Aguilar, José M. Mazarico, Luis Paz‐Ares
Abstract
Lurbinectedin is a marine-derived drug that inhibits transcription, a process that is frequently dysregulated in small cell lung cancer. The activity of lurbinectedin has been studied in many solid tumors, showing not only promising results but also a favorable safety profile. In relapsed small cell lung cancer, the drug has shown encouraging activity both as a single agent and in combination with doxorubicin, paclitaxel or irinotecan. The USA FDA has recently granted accelerated approval to lurbinectedin monotherapy in this setting. This article provides an update on available data and ongoing studies of lurbinectedin in small cell lung cancer, including Phase I combination trials, the basket Phase II trial and the ATLANTIS Phase III trial.